United States Neurovascular Embolization Devices Market Assessment, By Product, By Disease Pathology, By End Use, By Region, Opportunities, and Forecast, 2018-2032F

Improved access to healthcare services and insurance coverage in the United States have resulted in a more robust infrastructure for treatment of neurovascular patients. The United States Neurovascular Embolization Devices market was valued at 386.20 million in 2024 and is projected to be growing at a CAGR of 8.51% from 2025 to 2032. The increasing prevalence of hemorrhages & anomalies in cerebral arteries, rising cases of brain aneurysms, and arteriovenous malformations (AVMs) due to sedentary lifestyles are the main causes of surge in demand for neurovascular embolization devices. In addition, factors driving the growth of the United States neurovascular embolization devices market includes increasing geriatric population, increasing number of patients with hypertension and the introduction of novel neurovascular embolization devices.

An intravascular implant called a neurovascular embolization device is designed to permanently cut off blood supply to brain aneurysms and arteriovenous malformations.

Increasing Number of Patients with Cerebral Aneurysm Driving the Market

In recent years, there has been an increasing number of cerebral aneurysm patients in the United States, which has led to a growing demand for neurovascular embolization devices in the market. The market for these devices has been growing as more patients are diagnosed with cerebral aneurysms and seek treatment. Ruptured brain aneurysm affects around 6.7 million people in the United States, or one in every fifty people. Women above the age 55, have a higher risk of cerebral aneurysm rupture as compared to men.

Technological Advancements Accelerating the Market Growth

Technological advancements have made it possible to identify a size and shape of aneurysm. One major advancement is the development of new materials for embolization coils and flow diverters. These devices are used to block blood flow to abnormal blood vessels in the brain, and the new materials provide better visibility and control during the procedure. Additionally, there has been increased use of robotic systems for neurovascular procedures, which provide greater precision and control during the procedure.

Increasing Research Activities Support Market Expansion

The continuous emphasis on research activities has resulted in the creation of more sophisticated embolization devices, such as flow-diverting stents and liquid embolics, that have made the treatment of aneurysms and arteriovenous malformations more accessible. This improves the outcomes of the patients and enhances the success rate of neurovascular interventions. Increased investments in research enables a higher number of clinical trials and thus accelerates the regulatory approval process for new devices. Additionally, by focusing on research activities, medical technology companies are also able to ensure the development and availability of advanced technologies for effective management and treatment of chronic conditions.

For instance, in January 2023, Fluidx Medical Technology, Inc. release findings from their in vivo research for the Impass embolic device for middle meningeal artery (MMA) embolization for treating chronic subdural hematomas on the brain's surface. The device utilizes a low-viscosity, aqueous-based solution that solidifies into a durable embolus upon delivery. This technology aims to improve safety and efficacy during embolization procedures, potentially leading to better patient outcomes and increased adoption by healthcare providers, thus, supporting the market's expansion.

Cerebral Embolization and Aneurysm Coiling Devices Account for Majority of Market Share

Cerebral embolization and aneurysm coiling devices led the neurovascular device market. More than 40% of the market was accounted for cerebral embolization and aneurysm coiling devices, which are widely used in the treatment of aneurysms and strokes. Rising healthcare costs, increased R&D spending, and rising frequency of neurological diseases such as brain aneurysms, stroke, and arteriovenous malformations (AVMs) are few factors driving the market expansion.

Impact of COVID-19 on the United States Neurovascular Embolization Devices Market

The pandemic had a significant impact on the United States Neurovascular Embolization Device Market. The market has witnessed a decline in growth due to the pandemic's impact on healthcare facilities' operations, as well as a reduction in demand for non-urgent medical procedures. Additionally, the disruption of supply chains caused by the pandemic has led to delays in the production and distribution of neurovascular embolization devices, further impacting the market's growth. The market bounced back to pre-pandemic levels after upliftment of lockdown.

Impact of Russia-Ukraine War on the United States Neurovascular Embolization Devices Market

The Russia-Ukraine war did not have a significant impact on the United States neurovascular embolization market. Although, the war disrupted the trade dynamics such as demand-supply, pricing variances, impact on import/export and trading activities between United States, Russia, and Ukraine. Economic sanctions imposed by United States impacted the export of devices to Russia.

Key Players Landscape and Outlook

The market for neurovascular devices is competitive and is dominated by major players. The key players in the market are Terumo Corporation, Johnson & Johnson, and Medtronic Plc, Microport Scientific Corporation, Integra Life Sciences Corporation, Penumbra Inc and many others.

In 2021, Medtronic recalled two of its transcatheter devices intended to seal brain aneurysms: the Pipeline Flex Embolization Device and the Pipeline Flex Embolization Device with Shield Technology. The wire and tubes fractured and broke down when the delivery systems were used to place, remove, or relocate the stent within a patient.